Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer

Journal of Immunology

Volumn 190, Issue 8, 2013, Pages 4420-4430

  Leifler, Karin Söderlund ^a,b   Svensson, Susanne ^a,b   Abrahamsson, Annelie ^a,b   Bendrik, Christina ^a,b   Robertson, Jennifer ^c   Gauldie, Jack ^c   Olsson, Anna Karin ^d   Dabrosin, Charlotta ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Department of Clinical Immunology and Transfusion Medicine   (Sweden)

^c MCMASTER UNIVERSITY   (Canada)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ENDOSTATIN; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR REGRESSION;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; INFLAMMATION; MACROPHAGE ACTIVATION; MATRIX METALLOPROTEINASE 9; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEUTROPHIL INFILTRATION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; UP-REGULATION;

EID: 84875990758     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202610     Document Type: Article

References (55)

1. Duffy, M. J., T. M. Maguire, A. Hill, E. McDermott, and N. O'Higgins. 2000. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2: 252-257.
2. Stetler-Stevenson, W. G., and A. E. Yu. 2001. Proteases in invasion: matrix metalloproteinases. Semin. Cancer Biol. 11: 143-152.
3. Coussens, L. M., B. Fingleton, and L. M. Matrisian. 2002. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392.
4. Bendrik, C., J. Robertson, J. Gauldie, and C. Dabrosin. 2008. Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Cancer Res. 68: 3405-3412.
5. Hamano, Y., M. Zeisberg, H. Sugimoto, J. C. Lively, Y. Maeshima, C. Yang, R. O. Hynes, Z. Werb, A. Sudhakar, and R. Kalluri. 2003. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3: 589-601.
6. Nilsson, U. W., and C. Dabrosin. 2006. Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo. Cancer Res. 66: 4789-4794.
7. Pozzi, A., W. F. LeVine, and H. A. Gardner. 2002. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 21: 272-281.
8. Decock, J., S. Thirkettle, L. Wagstaff, and D. R. Edwards. 2011. Matrix metalloproteinases: protective roles in cancer. J. Cell. Mol. Med. 15: 1254-1265.
9. Visse, R., and H. Nagase. 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92: 827-839.
10. Partridge, J. J., M. A. Madsen, V. C. Ardi, T. Papagiannakopoulos, T. A. Kupriyanova, J. P. Quigley, and E. I. Deryugina. 2007. Functional analysis of matrix metalloproteinases and tissue inhibitors of metalloproteinases differentially expressed by variants of human HT-1080 fibrosarcoma exhibiting high and low levels of intravasation and metastasis. J. Biol. Chem. 282: 35964-35977.
11. Kopitz, C., M. Gerg, O. R. Bandapalli, D. Ister, C. J. Pennington, S. Hauser, C. Flechsig, H. W. Krell, D. Antolovic, K. Brew, et al. 2007. Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res. 67: 8615-8623.
12. Lipton, A., S. M. Ali, K. Leitzel, L. Demers, D. B. Evans, P. Hamer, S. Brown-Shimer, K. Pierce, and W. Carney. 2007. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 109: 1933-1939.
13. Miyagi, M., K. Aoyagi, S. Kato, and K. Shirouzu. 2007. The TIMP-1 gene transferred through adenovirus mediation shows a suppressive effect on peritoneal metastases from gastric cancer. Int. J. Clin. Oncol. 12: 17-24.
14. Klintman, M., S. Ørnbjerg Würtz, I. J. Christensen, P. Braemer Hertel, M. Fernö, M. Malmberg, H. Mouridsen, F. Cold, A. S. Schrohl, J. A. Foekens, et al. 2010. Association between tumor tissue TIMP-1 levels and objective response to firstline chemotherapy in metastatic breast cancer. Breast Cancer Res. Treat. 121: 365-371.
15. Schrohl, A. S., I. J. Christensen, A. N. Pedersen, V. Jensen, H. Mouridsen, G. Murphy, J. A. Foekens, N. Brunner, and M. N. Holten-Andersen. 2003. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol. Cell. Proteomics 2: 164-172.
16. Schrohl, A. S., M. P. Look, M. E. Meijer-van Gelder, J. A. Foekens, and N. Brünner. 2009. Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study. BMC Cancer 9: 322.
17. Rodríguez, D., C. J. Morrison, and C. M. Overall. 2010. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim. Biophys. Acta 1803: 39-54.
18. Murphy, G., A. Murthy, and R. Khokha. 2008. Clipping, shedding and RIPping keep immunity on cue. Trends Immunol. 29: 75-82.
19. Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell 144: 646-674.
20. Qian, B. Z., and J. W. Pollard. 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.
21. Mantovani, A., and A. Sica. 2010. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22: 231-237.
22. Movahedi, K., D. Laoui, C. Gysemans, M. Baeten, G. Stangé, J. Van den Bossche, M. Mack, D. Pipeleers, P. In't Veld, P. De Baetselier, and J. A. Van Ginderachter. 2010. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70: 5728-5739.
23. Sica, A., and A. Mantovani. 2012. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122: 787-795.
24. Rolny, C., M. Mazzone, S. Tugues, D. Laoui, I. Johansson, C. Coulon, M. L. Squadrito, I. Segura, X. Li, E. Knevels, et al. 2011. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19: 31-44.
25. Fridlender, Z. G., J. Sun, S. Kim, V. Kapoor, G. Cheng, L. Ling, G. S. Worthen, and S. M. Albelda. 2009. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16: 183-194.
26. Schaider, H., M. Oka, T. Bogenrieder, M. Nesbit, K. Satyamoorthy, C. Berking, K. Matsushima, and M. Herlyn. 2003. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int. J. Cancer 103: 335-343.
27. Dabrosin, C., P. J. Margetts, and J. Gauldie. 2003. Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer. Int. J. Cancer 107: 535-540.
28. Dabrosin, C., K. Palmer, W. J. Muller, and J. Gauldie. 2003. Estradiol promotes growth and angiogenesis in polyoma middle T transgenic mouse mammary tumor explants. Breast Cancer Res. Treat. 78: 1-6.
29. Bramson, J. L., F. L. Graham, and J. Gauldie. 1995. The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr. Opin. Biotechnol. 6: 590-595.
30. Lewis, C. E., M. De Palma, and L. Naldini. 2007. Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res. 67: 8429-8432.
31. Colognato, R., J. R. Slupsky, M. Jendrach, L. Burysek, T. Syrovets, and T. Simmet. 2003. Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells. Blood 102: 2645-2652.
32. Lee, E. J., M. S. Woo, P. G. Moon, M. C. Baek, I. Y. Choi, W. K. Kim, E. Junn, and H. S. Kim. 2010. Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J. Immunol. 185: 615-623.
33. López-Otín, C., and L. M. Matrisian. 2007. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 7: 800-808.
34. Martin, M. D., and L. M. Matrisian. 2007. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev. 26: 717-724.
35. Coussens, L. M., C. L. Tinkle, D. Hanahan, and Z. Werb. 2000. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481-490.
36. Pellikainen, J. M., K. M. Ropponen, V. V. Kataja, J. K. Kellokoski, M. J. Eskelinen, and V. M. Kosma. 2004. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin. Cancer Res. 10: 7621-7628.
37. Schäfer, S., S. Weibel, U. Donat, Q. Zhang, R. J. Aguilar, N. G. Chen, and A. A. Szalay. 2012. Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors. BMC Cancer 12: 366.
38. Bergers, G., R. Brekken, G. McMahon, T. H. Vu, T. Itoh, K. Tamaki, K. Tanzawa, P. Thorpe, S. Itohara, Z. Werb, and D. Hanahan. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2: 737-744.
39. Dabrosin, C. 2003. Increase of free insulin-like growth factor-1 in normal human breast in vivo late in the menstrual cycle. Breast Cancer Res. Treat. 80: 193-198.
40. Dabrosin, C. 2005. Microdialysis - an in vivo technique for studies of growth factors in breast cancer. Front. Biosci. 10: 1329-1335.
41. Dabrosin, C. 2005. Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo. Clin. Cancer Res. 11: 8036-8041.
42. Dabrosin, C., A. Hallström, U. Ungerstedt, and M. Hammar. 1997. Microdialysis of human breast tissue during the menstrual cycle. Clin. Sci. 92: 493-496.
43. Dabrosin, C., K. Ollinger, U. Ungerstedt, and M. Hammar. 1997. Variability of glutathione levels in normal breast tissue and subcutaneous fat during the menstrual cycle: an in vivo study with microdialysis technique. J. Clin. Endocrinol. Metab. 82: 1382-1384.
44. Bendrik, C., and C. Dabrosin. 2009. Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J. Immunol. 182: 371-378.
45. Biswas, S. K., and A. Mantovani. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11: 889-896.
46. Voronov, E., D. S. Shouval, Y. Krelin, E. Cagnano, D. Benharroch, Y. Iwakura, C. A. Dinarello, and R. N. Apte. 2003. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 100: 2645-2650.
47. Lindahl, G., N. Saarinen, A. Abrahamsson, and C. Dabrosin. 2011. Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer. Cancer Res. 71: 51-60.
48. Dinarello, C. A. 2010. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev. 29: 317-329.
49. Steenport, M., K. M. Khan, B. Du, S. E. Barnhard, A. J. Dannenberg, and D. J. Falcone. 2009. Matrix metalloproteinase (MMP)-1 and MMP-3 induce macrophage MMP-9: evidence for the role of TNF-alpha and cyclooxygenase-2. J. Immunol. 183: 8119-8127.
50. Tazawa, H., F. Okada, T. Kobayashi, M. Tada, Y. Mori, Y. Une, F. Sendo, M. Kobayashi, and M. Hosokawa. 2003. Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am. J. Pathol. 163: 2221-2232.
51. Lee, L. F., R. P. Hellendall, Y. Wang, J. S. Haskill, N. Mukaida, K. Matsushima, and J. P. Ting. 2000. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J. Immunol. 164: 2769-2775.
52. Granot, Z., E. Henke, E. A. Comen, T. A. King, L. Norton, and R. Benezra. 2011. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 20: 300-314.
53. Colombo, M. P., L. Lombardi, A. Stoppacciaro, C. Melani, M. Parenza, B. Bottazzi, and G. Parmiani. 1992. Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells. J. Immunol. 149: 113-119.
54. Daley, J. M., A. A. Thomay, M. D. Connolly, J. S. Reichner, and J. E. Albina. 2008. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J. Leukoc. Biol. 83: 64-70.
55. Stout, R. D., S. K. Watkins, and J. Suttles. 2009. Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. J. Leukoc. Biol. 86: 1105-1109.